Introduction {#s1}
============

Inflammation and host defense are energetically costly processes that must balance the use of host resources with an efficient containment of infection or injury. This is underpinned by the dynamic regulation of energy metabolism in immune cells in response to extrinsic signals, including cytokines, pathogen- and damage-associated molecular patterns, and tumor-derived metabolites ([@bib1]; [@bib4]; [@bib15]; [@bib19]; [@bib37]). For instance, activation of macrophages by bacterial products, such as lipopolysaccharide (LPS) from gram-negative bacteria, shifts core metabolic function towards increased reliance on aerobic glycolysis, with concomitant inhibition of mitochondrial respiration ([@bib14]; [@bib43]; [@bib50]). This depressed mitochondrial function appears to be by design, as this process serves multiple purposes. It leads to the so-called 'broken TCA cycle' that results, in part, from the shunting of citric acid to lipid synthesis ([@bib1]). Itaconate, also derived from citrate/aconitate, can modulate macrophage immune response through different mechanisms ([@bib26]; [@bib34]). By contrast, succinate accumulates through anaplerotic reactions, notably glutaminolysis ([@bib50]). Succinate oxidation to fumarate, mediated by succinate dehydrogenase (SDH)/ETC complex II activity, is a primary source of mitochondrial reactive oxygen species (mROS) in inflammatory macrophages that are involved in bactericidal activity ([@bib33]; [@bib54]). Succinate/SDH is believed to trigger mROS production through accumulation of reduced coenzyme Q leading to reverse electron transfer to ETC complex I ([@bib6]; [@bib42]). These findings demonstrate a well-orchestrated metabolic signaling event that occurs at the expense of reduced fuel economy and compromised mitochondrial function in macrophages.

In addition to their bacteria-killing effect, mROS stabilize hypoxia-inducible factor (Hif)-1α through inhibition of prolyl-hydroxylase enzymes that target Hif-1α for ubiquitination by the von Hippel--Lindau (Vhl) E3 ubiquitin ligase and subsequent proteasomal degradation ([@bib3]; [@bib21]). Hif-1α is a master transcriptional regulator of genes involved in glycolysis and anabolic metabolism, thereby supplementing the energetic needs of the broken TCA cycle ([@bib9]; [@bib32]; [@bib45]). Hif-1α is also required for the expression of the urea cycle enzyme arginase-1 (*Arg1*). Arg1 and nitric oxide synthase 2 were initially designated as markers for M2 and M1 macrophages, as these two enzymes convert the amino acid arginine to citrulline and nitric oxide, respectively. However, M1 activation also upregulates *Arg1* through Hif-1α. Similarly, in the nutrient-deprived tumor microenvironment, tumor-derived lactate has been proposed to increase Hif-1α activity in tumor-associated macrophages (TAMs) and thus to upregulate *Arg1* ([@bib8]). Aberrant expression of Arg1 in TAMs results in local arginine depletion that inhibits antitumor immunity mediated by cytotoxic T cells and natural killer (NK) cells ([@bib12]; [@bib48]). Accordingly, myeloid-specific deletion of *Hif1a* or *Arg1* suppresses tumor growth in mice ([@bib8]; [@bib12]). These observations suggest that the distinction between M1 and M2 activation may not be as clear in vivo and highlight the importance of energetic regulation in immune cell activation.

The circadian rhythm has been implicated in many biological and pathological processes, including the immune response and tumor progression ([@bib18]; [@bib35]; [@bib39]). The molecular clock includes the master regulator Bmal1 (or Aryl hydrocarbon receptor nuclear translocator-like protein 1, Arntl) and its transcriptional partner Clock, as well as the negative regulatory loop that includes Nr1d1, Nr1d2, period (Per1/2/3) and cryptochrome (Cry1/2) proteins, and the positive regulator loop that includes Rorα/β/γ ([@bib18]). Several nuclear receptors, such as the peroxisome proliferator-activated receptors, Pparα, Pparδ/β and Pparγ, are downstream of Bmal1/Clock and control the expression of clock output genes ([@bib5]; [@bib29]; [@bib57]). The circadian clock is both robust and flexible. It has been demonstrated that time-restricted feeding in mice can synchronize the peripheral clock separately from the central clock ([@bib11]), suggesting that a primary function of circadian rhythm is to maximize metabolic efficiency. In concert, we and others have shown that hepatic Bmal1 regulates rhythmic mitochondrial capacity in anticipation of nutrient availability ([@bib22]; [@bib40]). Prior studies have implicated the circadian oscillator in regulating macrophage inflammatory function. Notably, myeloid-specific *Bmal1* deletion disrupts diurnal monocyte trafficking and increases systemic inflammation and mortality in sepsis mouse models ([@bib35]). Whether and how the circadian clock controls the metabolism of immune cells to modulate their effector functions remains unclear.

In the present study, we describe a cell-autonomous role for Bmal1 in macrophage energetic regulation. Bmal1 is induced following macrophage inflammatory stimulation. Its loss-of-function exacerbates mitochondrial dysfunction, energetic stress and Hif-1α-dependent metabolic reprogramming. By using the B16-F10 melanoma model, we obtained results that demonstrate that the regulatory axis between Bmal1 and Hif-1α dictates macrophage energy investment that is relevant for discrete activation or polarization states, including activation of M1 and tumor-associated macrophages.

Results {#s2}
=======

The circadian clock is a transcriptional module induced by M1 activation {#s2-1}
------------------------------------------------------------------------

To assess transcriptional regulators that modulate the energetics and inflammatory function of macrophages, we performed RNA sequencing (RNA-seq) comparing interferon-γ (Ifn-γ) primed bone-marrow-derived macrophages (BMDM) without or with LPS stimulation (10 ng/mL for 8 hr, referred to as M1 activation). Gene ontology analysis using the DAVID platform was performed to identify clusters of transcription factors that were up- or downregulated in inflammatory macrophages, which were used to generate a protein--protein interaction map using STRING ([Table 1](#table1){ref-type="table"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Several activators of mitochondrial function or biogenesis were repressed, including *Myc* ([@bib28]), *Pparg*, Pparg co-activator 1 beta (*Ppargc1b*), and the mitochondrial transcription factor B1 (*Tfb1m*) and *Tfb2m*. On the other hand, the canonical inflammatory (e.g., *Nfkb1*/*2*, *Rela*/*b*, *Hif1a*, interferon regulatory factor 7 (*Irf7*) and *Irf8*) and stress response (e.g., *Atf3*, *Atf6b* and *Nfe2l2*) transcriptional modules were upregulated. Interestingly, clusters of circadian oscillator components (e.g., *Per1*, *Cry1*, *Nr1d1*, *Nr1d2* and *Rora*), as well as nuclear receptors downstream of the molecular clock (e.g., *Ppard* and its heterodimeric partner *Rxra*) ([@bib29]), were also induced.

###### Transcriptional regulators that are differentially regulated in M1-activated macrophages.

Genes encoding transcriptional regulators that were significantly induced or repressed by 8h M1 stimulation (p\<0.05, false discovery rate \[FDR\] \<0.05, \|F.C.\| \>1.5) in WT bone-marrow-derived macrophages (BMDM) were identified by gene ontology analysis using the DAVID platform. F.C., fold change. Differentially regulated genes that matched the Transcription GO term in the Biological Processes GO database (accession GO:0006350) were used to generate a protein--protein interaction map using String ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Uncharacterized zinc-finger proteins (ZFPs) were omitted from analyses by String.

  --------------------------- ---------- ----------- ---------- ---------- ---------- --------- ----------
  Induced (278 genes)                                                                           
  ADAR                        CRY1       GTF2A1      KDM4B      MNT        PPP1R10    Snapc1    Zkscan17
  AFF1                        CRY2       GTF2E2      KDM5B      MXD1       PPP1R13L   SNAPC2    ZMIZ1
  AFF4                        CSRNP1     GTF2F1      KDM5C      MXI1       PTOV1      SOX5      ZSCAN2
  AHR                         CSRNP2     HBP1        KEAP1      MYB        PTRF       SPEN      ZSCAN29
  AKNA                        DAXX       HDAC1       KLF11      NAB2       PURA       SPIC      ZXDB
  ANP32A                      DDIT3      HES1        KLF16      NACC1      RBPJ       SREBF1    
  ARHGAP22                    DDX54      HES7        KLF4       NCOA5      RCOR2      SRF       
  ARID3A                      DEDD2      HEXIM1      KLF7       NCOA7      REL        ST18      
  ARID5A                      DNMT3A     HIC1        KLF9       NCOR2      RELA       STAT2     
  ARNT2                       DPF1       HIC2        LCOR       NFAT5      RELB       STAT3     
  ASF1A                       DRAP1      HIF1A       LCORL      NFE2L2     REST       STAT4     
  ATF3                        E2F5       HIF3A       LHX2       NFIL3      RFX1       STAT5A    
  ATF4                        E4F1       HINFP       LIN54      NFKB1      RING1      TAF1C     
  ATF6B                       EAF1       HIVEP1      LITAF      NFKB2      RNF2       TAF7      
  ATXN7L3                     EDF1       HIVEP2      LMO4       NFKBIZ     RORA       TAL1      
  BANP                        EGR2       HIVEP3      MAF        NOTCH1     RREB1      TBL1X     
  BATF                        EID3       HLX         MAFF       NPTXR      RSLCAN18   TCEB2     
  BCL3                        EIF2C1     HMG20B      MAFG       NR1D1      RUNX2      TCF4      
  BCL6                        ELK1       HMGA1       MAFK       NR1D2      RUNX3      TGIF1     
  BCORL1                      ELL        HMGA1-RS1   MAML1      NR1H2      RUVBL2     THAP7     
  BHLHE40                     ELL2       HMGN5       MAX        NR1H3      RXRA       TLE2      
  BHLHE41                     ELL3       HOPX        MBD2       NR2F6      RYBP       TLE3      
  BRWD1                       EPAS1      HSF4        MDFIC      NR4A1      SAFB2      TRERF1    
  BTG2                        ERF        IFI205      MECP2      NR4A2      SAP130     TRIB3     
  CAMTA2                      ERN1       IFT57       MED13      NR4A3      SAP30      TRRAP     
  CASZ1                       ESRRA      ILF3        MED13L     PAF1       SBNO2      TSC22D4   
  CBX4                        ETS1       ING2        MED15      PAX4       SCAF1      TSHZ1     
  CCDC85B                     ETV3       IRF2BP1     MED25      PCGF3      SEC14L2    USP49     
  CDKN2A                      FIZ1       IRF4        MED26      PCGF5      SERTAD1    VPS72     
  CEBPB                       FLII       IRF7        MED28      PER1       SETD8      WHSC1L1   
  CEBPD                       FOXP1      IRF8        MED31      PER2       SFPI1      ZBTB17    
  CITED4                      FOXP4      JARID2      MEF2D      PHF1       SIN3B      ZBTB24    
  CREB5                       GATA2      JDP2        MIER2      PHF12      SIX1       ZBTB46    
  CREBBP                      GATAD2A    JMJD6       MIER3      PIAS4      SIX5       ZBTB7A    
  CREBL2                      GATAD2B    JUN         MITF       PML        SLC30A9    ZBTB7B    
  CREBZF                      GFI1       JUNB        MIXL1      POU2F2     SMAD3      ZEB1      
  CREM                        GLIS3      JUND        MKL1       POU3F1     SMAD4      ZFHX4     
  CRTC2                       GPBP1      KDM3A       MLL1       POU6F1     SMAD7      ZGPAT     
  CRTC3                       GRHL1      KDM4A       MNDA       PPARD      SMYD1      ZHX2      
                                                                                                
  **Repressed** (195 genes)                                                                     
  ACTL6A                      ELK3       IRF2        NAA15      SAP18                           
  AHRR                        ELP2       ITGB3BP     NCOA1      SAP25                           
  AI987944                    ELP3       KDM2B       NCOA3      SETD7                           
  ANG                         ELP4       KLF10       NFATC1     SETDB1                          
  ASCC1                       ENY2       KLF13       NFATC2     SNAPC5                          
  ASF1B                       ERCC8      KLF2        NFIA       SP3                             
  ATAD2                       ESR1       KLF8        NKRF       SSBP2                           
  AW146154                    ETOHI1     L3MBTL2     NPAT       SSRP1                           
  BCL9L                       ETV1       LBH         NPM3       STAT1                           
  CBFA2T3                     EYA1       LRPPRC      NR2C1      SUV39H1                         
  CBX3                        EYA4       LYL1        NRIP1      SUV39H2                         
  CBX6                        EZH2       MAFB        OVOL2      SUV420H2                        
  CBX8                        FLI1       MARS        PA2G4      TADA1                           
  CCNH                        FNTB       MBTPS2      PHF19      TADA2A                          
  CDCA7                       FOXM1      MCM2        PHTF2      TAF4B                           
  CDCA7L                      GTF2H2     MCM3        PNRC2      TAF9B                           
  CEBPA                       GTF2I      MCM4        POLR1B     TBX6                            
  CEBPG                       GTF2IRD1   MCM5        POLR2G     TCEA3                           
  CEBPZ                       GTF3A      MCM6        POLR2I     TCEAL8                          
  CHAF1A                      GTF3C5     MCM7        POLR3B     TCF7L2                          
  CHAF1B                      HABP4      MCM8        POLR3H     TFB1M                           
  CHD9                        HDAC10     MCTS1       POLR3K     TFB2M                           
  CHURC1                      HDAC11     MED14       PPARG      TFDP2                           
  CIITA                       HDAC2      MED18       PPARGC1B   THOC1                           
  CIR1                        HDAC6      MED22       PRIM1      TLE1                            
  CREB3                       HDAC7      MED27       PRIM2      TRAPPC2                         
  CREB3L1                     HDAC8      MEF2A       PRMT7      TRIM24                          
  CREB3L2                     HDAC9      MEF2C       PROX2      TWISTNB                         
  CTNND1                      HELLS      MEIS1       PSPC1      TXNIP                           
  CUX1                        HHEX       MLF1IP      RAD54B     UHRF1                           
  DDI2                        HIP1       MLL3        RB1        USF1                            
  DNMT1                       HIRA       MLLT3       RBAK       VGLL4                           
  DR1                         HMBOX1     MNAT1       RCBTB1     VPS36                           
  E2F1                        HMGA2      MPV17       RCOR3      WTIP                            
  E2F2                        HOXA1      MXD3        RERE       ZBTB3                           
  E2F6                        HTATSF1    MXD4        RFC1       ZBTB8A                          
  E2F7                        IKBKAP     MYBL2       RPAP1      ZHX1                            
  E2F8                        IKZF2      MYC         RSC1A1     ZIK1                            
  EGR3                        IL16       MYCBP2      RSL1       ZKSCAN4                         
  --------------------------- ---------- ----------- ---------- ---------- ---------- --------- ----------

We examined the expression of Bmal1, the non-redundant master regulator of circadian rhythm, and found that M1 activation ([Figure 1A](#fig1){ref-type="fig"}) or LPS treatment without Ifn-γ priming ([Figure 1B](#fig1){ref-type="fig"}) induced its mRNA and protein levels, which peaked at 12 hr after the stimulation. Because LPS was directly added to the cell culture without changing the medium, the induction of Bmal1 was not due to serum shock ([@bib49]). In fact, a one-hour LPS treatment in culture medium with 2% serum was sufficient to reset Bmal1 expression ([Figure 1C](#fig1){ref-type="fig"}) in a manner resembling serum shock (which requires a much higher serum concentration). Similar results were observed in mouse embryonic fibroblasts (MEFs), suggesting that the inflammatory regulation of Bmal1 was not macrophage-specific ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

![Macrophage Bmal1 is induced by M1 activation.\
(**A--C**) Bmal1 protein levels (top) and relative gene expression determined by qPCR (bottom) in bone-marrow-derived macrophages (BMDM) during a 24-hr time course of M1 activation (10 ng/ml Ifn-γ overnight priming + 10 ng/ml LPS) (**A**), treatment with LPS alone (100 ng/ml) (**B**), or acute LPS treatment for 1 hr (100 ng/mL) (**C**). For M1- and LPS-only treatments, LPS was spiked in at time zero without medium change. For acute LPS treatment, cells were grown with LPS for one hour followed by culture in DMEM, 2% FBS without LPS (time zero indicates medium change). N = 3 biological replicates were used for qPCR. (**D**) Relative expression of circadian clock and inflammatory transcriptional regulators in M1-activated macrophages, as determined by qPCR. N = 3 biological replicates, statistical analysis performed using two-way ANOVA for WT vs M-BKO across the time course. Data are presented as mean ± S.E.M. \*, p\<0.05. Experiments were repeated at least twice.](elife-54090-fig1){#fig1}

Myeloid-specific *Bmal1* knockout (M-BKO, *Bmal1^f/f^* crossed to *Lyz2-Cre*) mice were generated to determine the role of the circadian clock in macrophage function. *Bmal1^f/f^* was used as the wild-type control (WT). M-BKO did not affect M1 induction of canonical inflammatory regulators, such as *Nfkb1*, *Stat3*, *Hif1a* and *Myc* ([Figure 1D](#fig1){ref-type="fig"}). The expression of genes downstream of Bmal1, including *Nr1d2*, *Cry1* and *Ppard*, was dysregulated, and there was a further reduction of *Pparg* expression by M1 activation in M-BKO macrophages compared to WT cells ([Figure 1D](#fig1){ref-type="fig"}). By contrast, M2 activation by Il-4 did not regulate *Bmal1* mRNA levels, and Il-4-induced expression of *Arg1* and *Mgl2* was not altered by M-BKO ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). These results suggest that the circadian clock may function as a downstream effector of M1 stimulation in a cell-autonomous manner.

Bmal1 promotes mitochondrial metabolism in inflammatory macrophages {#s2-2}
-------------------------------------------------------------------

Because Pparδ/Pparγ are known regulators of mitochondrial function and energy substrate utilization in macrophages ([@bib10]; [@bib23]; [@bib27]; [@bib38]), we sought to determine the role of Bmal1 in macrophage bioenergetic control. In WT macrophages, M1 activation caused a progressive decrease in mitochondrial content, which was more pronounced in M-BKO macrophages ([Figure 2A](#fig2){ref-type="fig"}). The reduced mitochondrial content was accompanied by elevated protein levels of the mitophagy receptor Bnip3 ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). The Seahorse Mito Stress test also showed a steeper decline in oxygen consumption rate (OCR) following M1 treatment in M-BKO macrophages, compared to WT cells ([Figure 2B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Measurement of ETC complex activity in isolated mitochondria indicated that M-BKO caused a significant reduction in the activities of complexes II and III, given an equal amount of mitochondrial protein, 6 hr after M1 stimulation ([Figure 2C](#fig2){ref-type="fig"}). This suggests that macrophage *Bmal1* gene deletion also worsened M1-mediated suppression of mitochondrial function. To determine whether M-BKO affected the basal respiration and/or the recovery of mitochondrial homeostasis following inflammatory insults, we performed Mito Stress tests 24 hr after acute serum shock or LPS treatment, both of which synchronized *Bmal1* gene expression ([@bib49] and [Figure 1C](#fig1){ref-type="fig"}). There was no genotypic difference in the OCR at the resting state, and serum shock did not affect respiration in WT and M-BKO macrophages ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). By contrast, the basal OCR of M-BKO macrophages remained suppressed 24 hr following acute LPS treatment, whereas the basal OCR was completely recovered in WT macrophages ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). Thus, *Bmal1* gene deletion impacts macrophage mitochondrial respiration both during inflammatory stimulations and during the subsequent recovery phase.

![Bmal1 is required to maintain mitochondrial metabolism.\
(**A**) Assessment of mitochondrial mass in macrophages throughout a time course of M1 activation using Mitotracker Green (mean fluorescence intensity, MFI) determined by flow cytometry. N = 3 biological replicates, statistical analysis was performed using two-way ANOVA for WT vs M-BKO across the time course. (**B**) Basal oxygen consumption rate (OCR) in Ifn-γ-primed macrophages pretreated without or with LPS (10 ng/mL) for 2 or 6 hr before the assay. See [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"} for the full assay results. The assay medium contained minimal DMEM with 5 mM glucose and 1 mM sodium pyruvate, pH 7.4. N = 5 biological replicates, statistical analysis was performed using two-way ANOVA for WT vs M-BKO across the time course. (**C**) Activities of ETC complexes in isolated mitochondria from WT and M-BKO macrophages after 6 hours M1 stimulation. N = 3 biological replicates, statistical analysis was performed using Student's T test. (**D**) Extracellular flux analysis in Ifn-γ-primed macrophages measuring the changes in extracellular acidification rate (ECAR, left panel) and oxygen consumption rate (OCR, right panel) following LPS injection (100 ng/mL). The assay medium contained 5 mM glucose and 1 mM pyruvate in minimal DMEM with 2% dialyzed FBS, pH 7.4. N = 5 biological replicates, statistical analysis was performed using two-way ANOVA for WT vs M-BKO across the time course. (**E**) Glycolytic stress test in Ifn-γ-primed macrophages measuring ECAR following glucose (25 mM) injection, with or without LPS (100 ng/mL). Maximal glycolytic rate was determined by injection of oligomycin (OM, 2 μM), and glycolysis-dependent ECAR was determined by injection of 2-deoxyglucose (2-DG, 50 mM). The assay medium contained minimal DMEM with 2% dialyzed FBS, pH 7.4. N = 5 biological replicates, statistical analysis was performed using two-way ANOVA for WT vs M-BKO across the time course. Data are presented as mean ± S.E.M. \*, p\<0.05. Experiments were repeated at least twice.](elife-54090-fig2){#fig2}

Seahorse extracellular flux analysis showed that LPS injection increased the extracellular acidification rate (ECAR, indicative of lactic acid secretion) and decreased the oxygen consumption rate (OCR) of WT macrophages, as expected from aerobic glycolysis ([Figure 2D](#fig2){ref-type="fig"}). The ECAR and OCR were further enhanced and suppressed, respectively, in M-BKO macrophages. Similar results were obtained in thioglycollate-elicited peritoneal macrophages isolated from WT and M-BKO mice ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). By contrast, stable overexpression of *Bmal1* (Bmal1-OE) in RAW264.7 macrophages resulted in higher OCR and lower ECAR after LPS stimulation, compared to control cells ([Figure 2---figure supplement 1F-G](#fig2s1){ref-type="fig"}). To examine aerobic glycolysis directly, glucose was injected during the extracellular flux assay with or without co-injection of LPS. There was no difference in the basal glycolytic rate between WT and M-BKO macrophages ([Figure 2E](#fig2){ref-type="fig"}). LPS increased ECAR in both genotypes and to a greater extent in M-BKO macrophages. The induced ECAR could be blocked by injection of 2-deoxyglucose (2-DG), confirming that the acidification was caused by aerobic glycolysis. Furthermore, an increase in the glycolytic rate was observed in splenic macrophages from M-BKO mice isolated 6 hr after i.p. injection of LPS, which was accompanied by lowered circulating glucose levels, indicative of increased glucose consumption by inflammatory myeloid cells in M-BKO mice when compared to WT animals ([Figure 2---figure supplement 1H-I](#fig2s1){ref-type="fig"}).

To further assess the metabolic state, metabolomics analyses were employed to compare the cellular metabolite levels of WT and M-BKO macrophages 0, 6 and 12 hr after M1 activation ([Figure 3A--B](#fig3){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). As has been reported ([@bib50]), M1 activation caused accumulation of glycolytic intermediates (glucose-6-phosphate, fructose-6-phosphate and lactic acid) and depletion of TCA metabolites (e.g. citrate) but accumulation of succinate. Glycolytic metabolites and succinate were significantly higher in M-BKO macrophages than in WT cells. M-BKO cells also showed accumulation of several amino acids and intermediates of the urea cycle (which detoxifies ammonia released from amino-acid deamination) ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Consistent with the increased glycolytic metabolites, M1-stimulated glucose uptake and lactate production were higher in M-BKO macrophages than in WT cells ([Figure 3C--D](#fig3){ref-type="fig"}). These results suggest that *Bmal1* loss-of-function leads to metabolic dysregulation in M1-stimulated macrophages.

![*Bmal1* deletion induces a metabolic shift for glycolytic and amino-acid metabolism.\
(**A**) Summary of steady-state metabolomics data for differentially regulated metabolites from WT and M-BKO macrophages throughout a 12-hour M1 activation time course. Data are presented as heat maps (normalized to WT control for each metabolite, each panel is the average of four biological replicates). Statistical analysis was performed using two-way ANOVA for WT vs M-BKO across the time course. (**B**) Box plots of the relative abundances of select metabolites in panel (**A**). (**C**, **D**) Uptake of \[^3^H\]−2-deoxyglucose (C) and lactate secretion (D) in control or M1-activated macrophages. N = 3 biological replicates, statistical analysis was performed using Student's T test. Cell culture assays were repeated at least twice.\
Figure 3---source data 1.Metabolomics data for M1-activated WT and M-BKO macrophages.](elife-54090-fig3){#fig3}

Bmal1--Hif-1α crosstalk regulates macrophage energy metabolism {#s2-3}
--------------------------------------------------------------

As mentioned earlier, Hif-1α is a primary regulator of glucose metabolism in inflammatory macrophages. The enhanced aerobic glycolysis in M-BKO macrophages prompted us to examine whether Hif-1α activity was aberrantly elevated in these cells. Western blot analyses revealed that M1 activation led to a several-fold induction of Hif-1α protein levels in M-BKO macrophages compared to WT cells ([Figure 4A](#fig4){ref-type="fig"}), whereas Bmal1-OE RAW264.7 macrophages showed reduced Hif-1α protein ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). The expression of Hif-1α targets, such as lactate dehydrogenase A (*Ldha*), *Arg1* and *Il1b*, was enhanced by M-BKO and blocked by myeloid *Hif1a* knockout (M-HKO, [Figure 4B](#fig4){ref-type="fig"}). Hif-1α gene expression did not differ between WT and M-BKO cells ([Figure 1D](#fig1){ref-type="fig"}). mROS derived from increased succinate oxidation has previously been demonstrated to stabilize Hif-1α protein in inflammatory macrophages ([@bib33]). Metabolite analyses showed accumulation of succinate in M-BKO macrophages, suggesting that elevated mROS may be the cause of the increased Hif-1α protein. In fact, levels of mROS were higher in isolated mitochondria from M-BKO macrophages at 1 hr and 4 hr of M1 activation than in WT macrophages ([Figure 4C](#fig4){ref-type="fig"}). The addition of succinate increased mROS production in mitochondria from both WT and M-BKO macrophages. An additional two-fold induction of mROS was detected in mitochondria from 4-hr M1-stimulated M-BKO, but not in those from WT macrophages. Hif-1α protein accumulation could be normalized between genotypes by co-treatment with the antioxidant N-acetylcysteine (N-AC) or the competitive complex II inhibitor dimethylmalonate (DMM), which blocks mROS production ([Figure 4D](#fig4){ref-type="fig"}). Furthermore, M1-stimulated glucose uptake, lactate release and aerobic glycolysis were attenuated in myeloid-specific *Bmal1* and *Hif1a* double knockout macrophages (M-BHdKO; [Figure 4---figure supplement 1B-D](#fig4s1){ref-type="fig"}), indicating that the increased glucose utilization in M-BKO was Hif-1α-dependent.

![*Bmal1* loss-of-function increases oxidative stress and Hif-1α protein accumulation.\
(**A**) Immunoblots of Hif-1α and Bmal1 protein levels in WT and M-BKO macrophages during a 24-hr time course of M1 activation. (**B**) Relative expression of Hif-1α target genes in WT, M-BKO and M-HKO macrophages determined by qPCR. N = 3 biological replicates, statistical analysis was performed using two-way ANOVA for WT vs M-BKO or WT vs M-HKO across the time course. (**C**) Measurement of mROS using MitoSox Red (mean fluorescence intensity, MFI) in mitochondria isolated from control or M1-activated macrophages. Succinate (Suc, 10 mM) was included during MitoSox Red staining where indicated. N = 3 biological replicates, statistical analysis was performed using two-way ANOVA for WT vs M-BKO across the time course. (**D**) Hif-1α protein levels in control or 8-hr M1-activated macrophages co-treated with or without N-acetylcysteine (NAC) or 10 mM dimethylmalonate (DMM). Data are presented as mean ± S.E.M. \*, p\<0.05 for WT vs M-BKO and p\<0.05 for WT vs M-HKO. Experiments were repeated at least twice.](elife-54090-fig4){#fig4}

A previous study suggests that *Bmal1* deletion impairs the expression of *Nfe2l2* (which encodes Nrf2) and its downstream antioxidant genes, thereby increasing oxidative stress ([@bib13]). However, we found that expression of *Nfe2l2-* and Nrf2-induced oxidative stress responsive genes, such as NAD(P)H quinone dehydrogenase 1 (*Nqo1*; [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}), were upregulated in M-BKO macrophages upon M1 stimulation, suggesting that increased mROS associated with M-BKO was the cause rather than the consequence of dysregulated Nrf2 signaling. Collectively, these data indicate that Bmal1 and Hif-1α regulate opposing metabolic programs and that Bmal1-mediated mitochondrial metabolism serves to fine-tune Hif-1α activity by modulating oxidative stress.

*Bmal1* loss-of-function induces metabolic reprogramming toward amino-acid catabolism {#s2-4}
-------------------------------------------------------------------------------------

To characterize fully metabolic programs that were impacted by *Bmal1* loss of function, we compared RNA-seq data from control and M1-activated WT and M-BKO macrophages. These analyses revealed that the majority of M1-induced or -suppressed genes were regulated in a similar manner in WT and M-BKO macrophages, suggesting that *Bmal1* gene deletion affected specific inflammatory processes ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}) and in line with the intact expression pattern of Nfkb1 in M-BKO macrophages ([Figure 1D](#fig1){ref-type="fig"}). Gene ontology analyses indicated that the most enriched categories of M1-upregulated genes shared by both genotypes included regulation of apoptosis, response to stress and cytokine production. Among the top categories of suppressed genes were the cell cycle, DNA repair and carbohydrate metabolism. In the carbohydrate metabolism category, most TCA cycle enzymes were downregulated by M1 activation ([Figure 5A](#fig5){ref-type="fig"}).

![Genes involved in amino-acid uptake and catabolism are upregulated in M-BKO macrophages.\
(**A**) Schematic representation of M1-regulated genes involved in amino-acid and TCA metabolism determined by RNA-seq. Genes in blue are downregulated whereas genes in red are upregulated by 8 hours M1 activation in both WT and M-BKO macrophages. Genes that are differentially regulated in these two genotypes are displayed in heat maps on the right. F.C., fold change. N = 3 biological replicates. BCAAs, branch chain amino acids; Keto AAs, ketogenic amino acids; Cic, mitochondrial citrate carrier. (**B**) Relative expression of differentially regulated genes identified by RNA-seq and validated by qPCR in a 24-hr time course of M1 activation. N = 3 biological replicates, statistical analysis was performed using two-way ANOVA for WT vs M-BKO across the time course. (**C**) Hif-1α protein levels in control or 6-hr M1-activated macrophages with or without co-treatment of the neutral amino-acid transport inhibitor 2-amino-2-norbornanecarboxylic acid (BCH, 10 mM). (**D**) Gene expression in control or 6-hr M1-activated macrophages with or without co-treatment of 10 mM BCH and/or the complex II inhibitor dimethyl malonate (DMM, 10 mM) determined by qPCR. N = 3 biological replicates, statistical analysis was performed using Student's T test. Data are presented as mean ± S.E.M. \*, p\<0.05. Cell culture experiments were repeated at least twice.\
Figure 5---source data 1.Functional annotation clustering genes commonly and differentially regulated between WT and M-BKO BMDMs by 8 h M1 activation.](elife-54090-fig5){#fig5}

Direct comparison between M1-stimulated WT and M-BKO macrophages identified 419 genes that are more highly expressed in M1-activated M-BKO macrophages (FDR \< 0.05, p\<0.05, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Most-enriched categories included stress and inflammatory responses that contained *Il1b* and other Hif-1α target genes, such as *S100a8*/*S100a9* ([@bib17]). Other top enriched pathways were protein catabolism and amino-acid transport. These pathways included genes encoding plasma membrane amino-acid transporters (e.g., *Slc7a2*, *Slc7a8*, *Slc7a11*, *Slc38a2* and *Slc38a7*) as well as ubiquitin-activating, -conjugating and -ligating enzymes that target proteins for proteasomal degradation (e.g., ubiquitin-like modifier-activating enzyme 6 \[*Uba6*\], ubiquitin conjugating enzymes \[*Ube2q2* and *Ube2e3*\], ring finger proteins \[*Rnf12*, *Rnf56*, *Rnf128*, and *Rnf171\]*, cullin 3 \[*Cul3*\] and *Cul5*, and ubiquitin protein ligase e3a \[*Ube3a*\]) ([Figure 5A--B](#fig5){ref-type="fig"}). The expression of enzymes that are involved in the breakdown of branched-chain amino acids was also higher in M1-activated M-BKO cells, including branched-chain keto acid dehydrogenase E1 subunit beta (*Bckdhb*) and methylmalonate semialdehyde dehydrogenase (*Mmsdh*). These results are consistent with the increased amino-acid catabolism that was observed in metabolite assays ([Figure 3A](#fig3){ref-type="fig"}). Interestingly, certain genes described above, notably *Slc7a8*, appeared to be counter-regulated by Hif-1α, as their induction by M1 stimulation was blunted in M-HKO macrophages ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}).

Slc7a8, also called L-type amino-acid transporter 2 (Lat2), transports neutral amino acids that could be converted to succinate and could potentially contribute to Hif-1α protein stabilization. In line with increased amino acid-metabolism, extracellular flux analysis showed that M-BKO macrophages showed enhanced glutamine utilization compared to WT cells, which was blocked by 2-amino-bicyclo-(2,2,1)-heptane-2-carboxylate (BCH), an L-type amino-acid transporter inhibitor ([@bib7]; [@bib44]; [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). BCH decreased and normalized levels of Hif-1α protein between WT and M-BKO macrophages ([Figure 5C](#fig5){ref-type="fig"}). In addition, treatment with either BCH or DMM suppressed the expression of *Il1b*, *Slc7a8* and *Slc7a11* induced by M1 stimulation ([Figure 5D](#fig5){ref-type="fig"}). The combination of BCH and DMM did not exert a greater effect over that of DMM alone. Thus, amino-acid metabolism is upregulated in response to dysregulated energy metabolism in M-BKO macrophages, which contributes to increased oxidative stress and Hif-1α activation.

Macrophage *Bmal1* gene deletion promotes an immune-suppressive tumor-associated macrophage phenotype and enhances tumor growth {#s2-5}
-------------------------------------------------------------------------------------------------------------------------------

It has been suggested that myeloid-specific *Bmal1* deletion disrupts diurnal monocyte trafficking, thereby increasing sepsis-induced systemic inflammation and mortality ([@bib35]). Our results suggest that the cell-autonomous function of Bmal1 on macrophage metabolism and Hif-1α activation may contribute to the reported phenotype. Hif-1α regulates the polarization of M1 and tumor-associated macrophages, both of which are under energetically challenged conditions. We sought to determine whether Bmal1--Hif-1α crosstalk plays a role in modulating TAM activation through a mechanism similar to that in M1 stimulation. Treatment of macrophages with conditioned medium from primary B16-F10 tumors (T-CM) increased the expression of both *Bmal1* mRNA and Bmal1 protein ([Figure 6A](#fig6){ref-type="fig"}). When compared to WT macrophages, M-BKO macrophages showed enhanced mROS production and Hif-1α protein induced by T-CM ([Figure 6B--C](#fig6){ref-type="fig"}). Tracking with Hif-1α stabilization, aerobic glycolysis was upregulated by T-CM pretreatment in WT and to a greater extent in M-BKO macrophages ([Figure 6D](#fig6){ref-type="fig"}). T-CM elicited an energetic stress gene expression signature resembling that of M1 stimulation, which included upregulation of amino acid metabolism (*Arg1*, *Slc7a8* and *Bckdhb*) and oxidative stress (*Slc7a11* and *Nqo1*) pathways in WT macrophages that were further induced by M-BKO ([Figure 6E](#fig6){ref-type="fig"}).

![Bmal1 regulates tumor-associated macrophage polarization.\
(**A**) Bmal1 gene expression (left panel) and protein levels (right panel) in WT macrophages treated with control medium or increasing doses of B16-F10 tumor-conditioned medium (T-CM, diluted 1:3 or 1:1 with control medium) for 8 hr. N = 3 biological replicates for qPCR, statistical analysis was performed using Student's T test. (**B**) Measurement of mROS using MitoSox Red (mean fluorescent intensity, MFI) in mitochondria from macrophages treated with control medium or T-CM diluted 1:1 with control medium for 1 hr. N = 3 biological replicates, statistical analysis was performed using Student's T test. (**C**) Hif-1α protein levels in WT and M-BKO macrophages treated with control medium, T-CM diluted 1:1 with control medium, or undiluted T-CM for 4 hr. (**D**) Glycolytic stress test in macrophages pretreated with control medium or T-CM diluted 1:1 with control medium for 4 hr. N = 5 biological replicates. Statistical analysis was performed using two-way ANOVA comparing T-CM-treated M-BKO with WT cells across the time course. (**E**) Relative expression of genes involved in amino-acid metabolism and oxidative stress response in macrophages treated with control medium or T-CM diluted 1:3 with control medium for 8 hr, as determined by qPCR. N = 3 biological replicates, statistical analysis was performed using Student's T test. (**F**) Tumor volume in male (left) and female (right) WT and M-BKO mice. 300,000 B16-F10 cells were injected subcutaneously into the right flank. N = 18 (male) and 8 (female) mice, statistical analysis was performed using two-way ANOVA for WT vs M-BKO mice across the time course. (**G**) Gene expression for F4/80^+^ cells isolated from B16-F10 tumors or spleens of female mice 14 days after injection. Tissues from six mice per genotype were pooled into three groups for leukocyte isolation. Statistical analysis was performed using Student's T test. Data are presented as mean ± S.E.M. \*, p\<0.05. Experiments were repeated at least twice.](elife-54090-fig6){#fig6}

Subsequently, we employed a mouse model of melanoma through subcutaneous injection of B16-F10 melanoma cells to assess the impact of myeloid *Bmal1* deletion on tumor growth. Tumor volume was increased in both male and female M-BKO mice compared to WT controls ([Figure 6F](#fig6){ref-type="fig"}). Furthermore, the expression of *Arg1*, *Slc7a8* and *Slc7a11* was upregulated in F4/80^+^ cells isolated from tumors but not spleens of M-BKO mice compared to WT animals ([Figure 6G](#fig6){ref-type="fig"}). Of note, the mRNA levels of *Arg1*, *Slc7a8* and *Slc7a11* were substantially higher in tumor than in splenic F4/80^+^ cells. Flow cytometry analyses of F4/80^+^ cells from primary tumors stained with Mitosox Red and 2-deoxy-2-\[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino\]-D-glucose (2-NBDG) were employed to assess mROS production and glucose uptake, respectively. M-BKO TAMs exhibited a trend towards increased mROS and significantly higher glucose uptake, compared to WT TAMs ([Figure 6---figure supplement 1A-C](#fig6s1){ref-type="fig"}). These results demonstrate that the metabolic reprogramming observed in T-CM-primed BMDM is shared by TAMs.

To confirm that macrophage Bmal1 modulates tumor growth cell-autonomously and to assess the effect of TAMs on anti-tumor immune response within the same host environment, we co-injected B16-F10 cells with either WT or M-BKO macrophages into the right or left flanks, respectively, of WT mice. Tumor growth rate was substantially higher when the tumor cells were co-injected with M-BKO macrophages than when co-injected with WT cells ([Figure 7A](#fig7){ref-type="fig"}). In concert, co-injection with M-BKO macrophages led to a reduction in the CD8^+^ T cell population among tumor-infiltrating CD45^+^ leukocytes, as well as to functionally primed CD8^+^ T and NK cells that expressed Ifn-γ protein following stimulation with phorbol myristate acetate and ionomycin ex vivo ([Figure 7B](#fig7){ref-type="fig"}). Similar results were obtained when the co-injections were performed in M-BKO mice ([Figure 7---figure supplement 1A, B](#fig7s1){ref-type="fig"}).

![Macrophage Bmal1 modulates the antitumor activity.\
(**A**) Tumor volume in WT male mice co-injected with 500,000 B16-F10 cells and either 500,000 WT or M-BKO macrophages as indicated. N = 22 mice, statistical analysis was performed using two-way ANOVA to compare WT vs M-BKO macrophage co-injection across the time course. (**B**) Flow cytometric analysis of tumor-infiltrating CD8^+^ T cells (CD45^+^CD3^+^CD8a^+^ cells, left panel) and NK cells (CD45^+^CD3^--^NK1.1^+^ cells, right panel) stimulated ex vivo with phorbol 12-myristate 13-acetate and ionomycin for Ifn-γ co-staining. Tumors represented in panel (**A**) were pooled into three groups prior to isolation of infiltrating leukocytes for flow cytometry. Statistical analysis was performed using Student's T test. (**C**) Tumor volume in WT male mice co-injected with 500,000 B16-F10 cells and either 500,000 WT or M-BKO macrophages, supplemented without or with dimethylmalonate (DMM, approximately 150 mg/kg body weight per day in mouse diet). N = 8 mice, statistical analysis was performed using two-way ANOVA to compare WT vs M-BKO macrophage co-injection on control diet, or to compare WT macrophage co-injection on the control diet vs WT or M-BKO macrophage co-injection on the DMM-supplemented diet across the time course. Data are presented as mean ± S.E.M. \*, p\<0.05. Experiments were repeated at least twice.](elife-54090-fig7){#fig7}

We next sought to address the importance of oxidative stress in TAM activation. Similar to M1 macrophages, DMM blocked Hif-1α protein accumulation and attenuated *Arg1* upregulation in T-CM-treated macrophages ([Figure 7---figure supplement 1C-D](#fig7s1){ref-type="fig"}). Administering DMM (\~150 mg/kg body/day) at the time of macrophage-tumor cell co-inoculation effectively suppressed melanoma tumor growth and normalized the difference in tumor promoting effects between WT and M-BKO macrophages ([Figure 7C](#fig7){ref-type="fig"}). These results reveal a unifying mechanism by which Bmal1 controls macrophage effector functions through bioenergetic regulation, and suggest that targeting oxidative stress may provide a means to modulate the anti-tumor activity of TAMs.

Discussion {#s3}
==========

It has been reported that sepsis exerts a long-lasting effect on circadian rhythm alteration in mice ([@bib31]; [@bib36]). In the current study, we show that inflammatory stimulants, including Ifn-γ/LPS and tumor-derived factors, control the expression of the circadian master regulator Bmal1 in the macrophages. Our data further demonstrate that Bmal1 is an integral part of the metabolic regulatory network and modulates macrophage activation, in part through crosstalk with Hif-1α. The Bmal1--Hif-1α regulatory loop regulates the balance between oxidative and glycolytic metabolism in energetically stressed macrophages that have distinct effector functions. *Bmal1* loss-of-function in M1-activated macrophages causes mitochondrial dysfunction, thereby potentiating mROS production and Hif-1α protein stabilization, which probably contributes to the increased sepsis-induced inflammatory damage reported for M-BKO mice ([@bib35]). Within the tumor microenvironment, macrophage *Bmal1* gene deletion leads to compromised anti-tumor immunity and accelerated tumor growth in a mouse melanoma model. Therefore, the Bmal1--Hif-1α nexus serves as a metabolic switch that may be targeted to control macrophage effector functions.

Much attention has been focused on how inflammatory stimuli disrupt mitochondrial metabolism as a means to generate signaling molecules, including TCA metabolites and mROS. The analysis of transcriptional modules that are involved in macrophage inflammatory response reveals a coordinated effort in the control of mitochondrial activity. The expression of several regulators of mitochondrial biogenesis (e.g., *Pparg*) is downregulated rapidly after M1 stimulation and rebounds after between 8--12 hr, when *Bmal1* and *Ppard* expression is induced ([Figure 1](#fig1){ref-type="fig"}). Several lines of evidence indicate that Bmal1 plays a key role in restoring mitochondrial function and in modulating a Hif-1α-mediated inflammatory response. The expression of transcription factors that are known to control mitochondrial bioenergetics (i.e., Pparγ and Pparδ) is downregulated by M-BKO. Macrophages that are deficient in *Bmal1* are unable to sustain mitochondrial function upon M1 stimulation and fail to recover from suppressed mitochondrial respiration 24 hr following acute LPS treatment. By contrast, Bmal1 gain-of-function in RAW 246.7 macrophages promotes oxidative metabolism. It is interesting to note that the dysregulated mitochondrial respiration phenotype of M-BKO macrophages occurs as early as 2 hr after M1 activation, whereas Bmal1 protein accumulation peaks at 12 hr. This early phase of regulation could be mediated by downstream pathways of the circadian regulatory network. RNA-seq analyses reveal that components of the molecular clock are induced by M1 ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Notably, Nr1d1/Nr1d2 have been shown to regulate macrophage inflammatory gene expression negatively ([@bib24]) and promote mitochondrial function in skeletal muscle ([@bib55]). The induction of *Nr1d2* by M1 was almost completely abolished in M-BKO macrophages ([Figure 1D](#fig1){ref-type="fig"}). In concert, the expression of *Cx3cr1*, a direct target suppressed by Nr1d1/Nr1d2 ([@bib24]), is higher in M1-activated M-BKO macrophages than in WT cells ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). This suppressive effect of Nr1d1/Nr1d2 may dampen the inflammatory damage to mitochondrial function at the initial stage of M1 activation. Another potential mechanism is through enhanced Hif-1α activity by M-BKO, which is evident after 4 hr of M1 activation ([Figure 4A](#fig4){ref-type="fig"}). Hif-1α suppresses mitochondrial respiration through multiple mechanisms ([@bib51]). For instance, it regulates the glycolytic program favoring lactate production and controls the expression of Bnip3 to promote mitophagy. M-BKO macrophages exhibit a higher lactate production rate 4 hr after M1 stimulation ([Figure 3D](#fig3){ref-type="fig"}) and this phenotype was observed as early as 2 hr after M1 stimulation (data not shown). Bnip3 protein accumulation is also increased, although appreciable amounts of Bnip3 protein could only be detected at 8 hr after M1 treatment ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Bmal1 is best known for its role in circadian regulation and has been shown to control rhythmic monocyte recruitment, which plays a key role in the immune response against pathogens and in limiting infection-associated inflammatory damage ([@bib35]). Our data suggest that LPS or M1 stimulation could 'reset the clock' by inducing/resynchronizing the expression of *Bmal1*. In this context, Bmal1 may regulate energy metabolism to support diurnal monocyte trafficking, and may control the timing of glycolytic to oxidative metabolism transition during M1 activation that dictates the extent of Hif-1α activation and the associated inflammatory response.

Both Bmal1 and Hif-1α belong to the basic helix-loop-helix (bHLH) transcription factor family and have similar domain structures. However, they appear to regulate opposing metabolic programs, with Hif-1α serving as a master regulator of aerobic glycolysis and Bmal1 as a positive regulator of oxidative metabolism ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). The crosstalk between these two bHLH transcription factors is in part mediated by succinate and SDH/complex II-facilitated mROS production. Succinate is one of the entry points for anerplerosis that attempts to replenish the TCA cycle metabolites that are depleted by disruption of mitochondrial oxidative metabolism. Increased protein or amino-acid catabolism provides a source of anerplerotic reactions. Succinate accumulation and the subsequent oxidation to fumarate, however, generate mROS, which stabilize Hif-1α protein and thus drive aerobic glycolysis. Our data suggest that amino-acid metabolism appears to be down- and upregulated by Bmal1 and Hif-1α, respectively, as demonstrated by the regulation of *Arg1* and *Slc7a8* gene expression. As described above, Hif-1α has also been shown to regulate Bnip3-mediated mitophagy that reduces mitochondrial oxidative capacity ([@bib58]). Therefore, Bmal1-controlled mitochondrial metabolism provides a break to this feedforward cycle that limits inflammatory damage. In line with this, previous work has demonstrated that myeloid *Bmal1* knockout mice have reduced survival rate upon *L. monocytogenes* infection ([@bib35]). These observations indicate a tightly regulated metabolic program in the macrophage that executes effector functions and places Bmal1-regulated mitochondrial metabolism at the center of an orderly and balanced immune response.

Despite being characterized as M2-like, TAMs share several common features with M1-activated macrophages: both function under nutrient-restricted conditions and Hif-1α is required for their activation. Previous studies implicate a glycolytic preference for TAMs in breast, thyroid, and pancreatic cancer ([@bib2]; [@bib30]; [@bib41]). Our data confirm that T-CM treatment enhances glycolysis in the macrophage accompanied by increased Hif-1α protein ([Figure 6C, D](#fig6){ref-type="fig"}). *Arg1*, originally defined as an M2 marker, is a *bona fide* target of Hif-1α that is upregulated in TAMs and M1 macrophages. Arg1 is involved in the urea cycle that detoxifies ammonia, and its induction supports the upregulation of amino-acid catabolism. M-BKO macrophages show increased mROS, glycolytic metabolism, Hif-1α stabilization and upregulation of *Arg1* and *Slc7a8* upon treatment with T-CM. Dysregulated amino-acid metabolism has been shown to impact immune cell activation. Arginine depletion impairs lymphocyte function, as arginine is required for effector T cell and NK cell proliferation and maintenance ([@bib16]; [@bib25]; [@bib48]). Slc7a8 transports neutral amino acids, including branched-chain amino acids that are essential for lymphocyte activation and cytotoxic function ([@bib46]; [@bib52]). Therefore, the increased amino-acid utilization by M-BKO macrophages may contribute to the observed reduction in populations of Ifn-γ-producing CD8^+^ T and NK cells in tumor-infiltrating CD45^+^ leukocytes ([Figure 7B](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). The fact that amino-acid or protein metabolism and oxidative stress genes (*Arg1*, *Slc7a8* and *Slc7a11*) are upregulated in TAMs, compared to splenic macrophages ([Figure 6G](#fig6){ref-type="fig"}), supports the notion that energetic stress is also a key determinant of TAM polarization. As a proof-of-principle approach, we show that DMM treatment blocks T-CM induced Hif-1α protein stabilization in vitro and suppresses tumor growth in vivo. Thus, M1 macrophages opt for an inefficient way to produce ATP, whereas TAMs are limited in energy allocations. Both of these processes result in an energetically challenged state in which Bmal1--Hif-1α crosstalk controls the metabolic adaptation that shapes macrophage polarization. Future studies investigating mechanisms that harness this energetic stress may identify means to modulate immune cell functions effectively.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                                                   Source or reference         Identifiers                                                                      Additional\
  (species) or resource                                                                                                                                                                                                                   information
  -------------------------------------------- ----------------------------------------------------------------------------- --------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------
  Strain, strain background (*Mus musculus*)   B6.129S4(CG)-*Arntl^tm1Weit^*/J                                               The Jackson Laboratory      JAX: 007668                                                                      Carry loxp sites flanking exon 8 of the *Bmal1* gene

  Strain, strain background (*Mus musculus*)   B6.129-*Hif1a^tm3Rsjo^*/J                                                     The Jackson Laboratory      JAX: 007561                                                                      Carry loxp sites flanking exon 2 of the *Hif1a* gene

  Strain, strain background (*Mus musculus*)   B6.129P2-*Lyz2^tm1(cre)lfo^*/J                                                The Jackson Laboratory      JAX: 004781                                                                      Myeloid-specific Cre recombinase expression

  Antibody                                     Mouse monoclonal anti-Bmal1 (clone B-1)                                       Santa Cruz Biotechnology    Cat\# sc365645; RRID:[AB_10841724](https://scicrunch.org/resolver/AB_10841724)   WB (1:1000)

  Antibody                                     Rabbit polyclonal anti-Hif-1α                                                 Novus Biologicals           Cat\# NB100-449;\                                                                WB (1:1000)
                                                                                                                                                         RRID:[AB_10001045](https://scicrunch.org/resolver/AB_10001045)                   

  Antibody                                     Rabbit monoclonal anti-Bnip3\                                                 Abcam                       Cat\# ab109362;\                                                                 WB (1:1000)
                                               (clone EPR4034)                                                                                           RRID:[AB_10864714](https://scicrunch.org/resolver/AB_10864714)                   

  Antibody                                     Rabbit polyclonal anti-β-tubulin                                              Cell Signaling Technology   Cat\# 2146;\                                                                     WB (1:1000)
                                                                                                                                                         RRID:[AB_2210545](https://scicrunch.org/resolver/AB_2210545)                     

  Antibody                                     Rabbit monoclonal anti-β-Actin (clone 13E5)                                   Cell Signaling Technology   Cat\# 4970;\                                                                     WB (1:1000)
                                                                                                                                                         RRID:[AB_2223172](https://scicrunch.org/resolver/AB_2223172)                     

  Antibody                                     Rat monoclonal anti-CD45 (clone 30-F11), PerCP/Cy5.5-conjugated               Biolegend                   Cat\# 103132;\                                                                   Flow cytometry (1 μL per test)
                                                                                                                                                         RRID:[AB_893340](https://scicrunch.org/resolver/AB_893340)                       

  Antibody                                     Armenian hamster monoclonal anti-CD3ε (clone 145--2 C11), PE/Cy7-conjugated   Biolegend                   Cat\# 100320;\                                                                   Flow cytometry (2.5 μL per test)
                                                                                                                                                         RRID:[AB_312685](https://scicrunch.org/resolver/AB_312685)                       

  Antibody                                     Rat monoclonal anti-CD8a (clone 53--6.7), Alexa Fluor 700-conjugated          Biolegend                   Cat\# 100730;\                                                                   Flow cytometry (0.5 μL per test)
                                                                                                                                                         RRID:[AB_493703](https://scicrunch.org/resolver/AB_493703)                       

  Antibody                                     Mouse monoclonal anti-NK1.1 (clone PK136), APC-conjugated                     Biolegend                   Cat\# 108710                                                                     Flow cytometry (5 μL per test)

  Antibody                                     Rat monoclonal anti-F4/80 (clone BM8), Alexa Fluor 488-conjugated             Biolegend                   Cat\# 123120;\                                                                   Flow cytometry (5 μL per test)
                                                                                                                                                         RRID:[AB_893479](https://scicrunch.org/resolver/AB_893479)                       

  Antibody                                     Rat monoclonal anti-F4/80 (clone BM8), APC-conjugated                         Biolegend                   Cat\# 123115;\                                                                   Flow cytometry (2.5 μL per test)
                                                                                                                                                         RRID:[AB_893493](https://scicrunch.org/resolver/AB_%20893493)                    

  Antibody                                     Rat monoclonal anti-Ifn-γ (clone XMG1.2), PE-conjugated                       ThermoFisher Scientific     Cat\# 12-7311-81, RRID:[AB_466192](https://scicrunch.org/resolver/AB_466192)     Flow cytometry (1 μL per test)

  Peptide, recombinant protein                 Recombinant murine interferon-γ                                               Peprotech                   Cat\# 315--05                                                                    Used 10 ng/mL final concentration

  Peptide, recombinant protein                 Recombinant murine interleukin-4                                              Peprotech                   Cat\# 214--14                                                                    Used 10 ng/mL final concentration

  Sequence-based reagent                       36b4_F                                                                        This paper                  qPCR primer                                                                      AGATGCAGCAGATCCGCAT

  Sequence-based reagent                       36b4_R                                                                        This paper                  qPCR primer                                                                      GTTCTTGCCCATCAGCACC

  Sequence-based reagent                       Arg1_F                                                                        This paper                  qPCR primer                                                                      CGTAGACCCTGGGGAACACTAT

  Sequence-based reagent                       Arg1_R                                                                        This paper                  qPCR primer                                                                      TCCATCACCTTGCCAATCCC

  Sequence-based reagent                       Bckdhb_F                                                                      This paper                  qPCR primer                                                                      TGGGGCTCTCTACCATTCTCA

  Sequence-based reagent                       Bckdhb_R                                                                      This paper                  qPCR primer                                                                      GGGGTATTACCACCTTGATCCC

  Sequence-based reagent                       Bmal1_F                                                                       This paper                  qPCR primer                                                                      AGGATCAAGAATGCAAGGGAGG

  Sequence-based reagent                       Bmal1_R                                                                       This paper                  qPCR primer                                                                      TGAAACTGTTCATTTTGTCCCGA

  Sequence-based reagent                       cMyc_F                                                                        This paper                  qPCR primer                                                                      CAGCGACTCTGAAGAAGAGCA

  Sequence-based reagent                       cMyc_R                                                                        This paper                  qPCR primer                                                                      GACCTCTTGGCAGGGGTTTG

  Sequence-based reagent                       Cry1_F                                                                        This paper                  qPCR primer                                                                      CACTGGTTCCGAAAGGGACTC

  Sequence-based reagent                       Cry1_R                                                                        This paper                  qPCR primer                                                                      CTGAAGCAAAAATCGCCACCT

  Sequence-based reagent                       Gclc_F                                                                        This paper                  qPCR primer                                                                      CATCCTCCAGTTCCTGCACA

  Sequence-based reagent                       Gclc_R                                                                        This paper                  qPCR primer                                                                      ATGTACTCCACCTCGTCACC

  Sequence-based reagent                       Hif1a_F                                                                       This paper                  qPCR primer                                                                      GAACGAGAAGAAAAATAGGATGAGT

  Sequence-based reagent                       Hif1a_R                                                                       This paper                  qPCR primer                                                                      ACTCTTTGCTTCGCCGAGAT

  Sequence-based reagent                       Hmox1_F                                                                       This paper                  qPCR primer                                                                      CAGAGCCGTCTCGAGCATAG

  Sequence-based reagent                       Hmox1_R                                                                       This paper                  qPCR primer                                                                      CAAATCCTGGGGCATGCTGT

  Sequence-based reagent                       Il1b_F                                                                        This paper                  qPCR primer                                                                      AGCTTCAGGCAGGCAGTATC

  Sequence-based reagent                       Il1b_R                                                                        This paper                  qPCR primer                                                                      AAGGTCCACGGGAAAGACAC

  Sequence-based reagent                       Ldha_F                                                                        This paper                  qPCR primer                                                                      GCGTCTCCCTGAAGTCTCTT

  Sequence-based reagent                       Ldha_R                                                                        This paper                  qPCR primer                                                                      GCCCAGGATGTGTAACCTTT

  Sequence-based reagent                       Mgl2_F                                                                        This paper                  qPCR primer                                                                      ccttgcgtttgtcaaaacatgac

  Sequence-based reagent                       Mgl2_R                                                                        This paper                  qPCR primer                                                                      ctgaggcttatggaactgaggc

  Sequence-based reagent                       Mmsdh_F                                                                       This paper                  qPCR primer                                                                      GAGGCCTTCAGGTGGTTGAG

  Sequence-based reagent                       Mmsdh_R                                                                       This paper                  qPCR primer                                                                      GATAGATGGCATGGTCTCTCCC

  Sequence-based reagent                       Nfe2l2_F                                                                      This paper                  qPCR primer                                                                      GGTTGCCCACATTCCCAAAC

  Sequence-based reagent                       Nfe2l2_R                                                                      This paper                  qPCR primer                                                                      GCAAGCGACTCATGGTCATC

  Sequence-based reagent                       Nfkb1_F                                                                       This paper                  qPCR primer                                                                      CCTGCTTCTGGAGGGTGATG

  Sequence-based reagent                       Nfkb1_R                                                                       This paper                  qPCR primer                                                                      GCCGCTATATGCAGAGGTGT

  Sequence-based reagent                       Nqo1_F                                                                        This paper                  qPCR primer                                                                      TCTCTGGCCGATTCAGAGTG

  Sequence-based reagent                       Nqo1_R                                                                        This paper                  qPCR primer                                                                      TGCTGTAAACCAGTTGAGGTTC

  Sequence-based reagent                       Nr1d2_F                                                                       This paper                  qPCR primer                                                                      TCATGAGGATGAACAGGAACCG

  Sequence-based reagent                       Nr1d2_R                                                                       This paper                  qPCR primer                                                                      CGGCCAAATCGAACAGCATC

  Sequence-based reagent                       Ppard_F                                                                       This paper                  qPCR primer                                                                      CAGCCTCAACATGGAATGTC

  Sequence-based reagent                       Ppard_R                                                                       This paper                  qPCR primer                                                                      TCCGATCGCACTTCTCATAC

  Sequence-based reagent                       Pparg_F                                                                       This paper                  qPCR primer                                                                      CAGGAGCCTGTGAGACCAAC

  Sequence-based reagent                       Pparg_R                                                                       This paper                  qPCR primer                                                                      ACCGCTTCTTTCAAATCTTGTCTG

  Sequence-based reagent                       Slc7a2_F                                                                      This paper                  qPCR primer                                                                      CCCGGGATGGCTTACTGTTT

  Sequence-based reagent                       Slc7a2_R                                                                      This paper                  qPCR primer                                                                      AGGCCATCACAGCAGAAATGA

  Sequence-based reagent                       Slc7a8_F                                                                      This paper                  qPCR primer                                                                      GAACCACCCGGGTTCTGAC

  Sequence-based reagent                       Slc7a8_R                                                                      This paper                  qPCR primer                                                                      TGATGTTCCCTACAATGATACCACA

  Sequence-based reagent                       Slc7a11_F                                                                     This paper                  qPCR primer                                                                      ATCTCCCCCAAGGGCATACT

  Sequence-based reagent                       Slc7a11_R                                                                     This paper                  qPCR primer                                                                      GCATAGGACAGGGCTCCAAA

  Sequence-based reagent                       Stat3_F                                                                       This paper                  qPCR primer                                                                      TGGCAGTTCTCGTCCAC

  Sequence-based reagent                       Stat3_R                                                                       This paper                  qPCR primer                                                                      CCAGCCATGTTTTCTTTGC

  Sequence-based reagent                       Bmal1_F                                                                       This paper                  Cloning primers                                                                  GGCGAATTCGCGGACCAGAGAATGGAC

  Sequence-based reagent                       Bmal1_R                                                                       This paper                  Cloning primers                                                                  GGGCTCGAGCTACAGCGGCCATGGCAA

  Cell line (*Mus musculus*)                   RAW264.7 macrophages                                                          ATCC                        qPCR primer                                                                      TIB-71

  Cell line (*Mus musculus*)                   B16-F10 melanoma cells                                                        ATCC                        qPCR primer                                                                      CRL-6475

  Recombinant DNA reagent                      pBABE-puro retroviral expression vector (plasmid)                             Addgene                     Plasmid \#1764                                                                   

  Recombinant DNA reagent                      pBABE-Bmal1 (plasmid)                                                         This study                                                                                                   For stable overexpression of mouse *Bmal1*

  Chemical compound, drug                      Lipopolysaccharides from *Escherichia coli* K-235                             Sigma-Aldrich               Cat\# L2143                                                                      Final concentration used varied as indicated

  Chemical compound, drug                      Dimethyl malonate                                                             Sigma-Aldrich               Cat\# 136441;\                                                                   Used 10 mM final concentration
                                                                                                                                                         CAS: 108-59-8                                                                    

  Chemical compound, drug                      Sodium succinate dibasic                                                      Sigma-Aldrich               Cat\# 14160;\                                                                    Used 10 mM final concentration
                                                                                                                                                         CAS: 150-90-3                                                                    

  Chemical compound, drug                      N-acetyl-L-cysteine                                                           Sigma-Aldrich               Cat\# A9165;\                                                                    Final concentration used varied as indicated.
                                                                                                                                                         CAS: 616-91-1                                                                    

  Chemical compound, drug                      2-deoxy-D-glucose                                                             Sigma-Aldrich               Cat\# D8375;\                                                                    Used 50 mM final concentration
                                                                                                                                                         CAS: 154-17-6                                                                    

  Chemical compound, drug                      Quant-iT ribogreen RNA reagent                                                ThermoFisher Scientific     Cat\# R11491                                                                     

  Chemical compound, drug                      Mitotracker green FM                                                          ThermoFisher Scientific     Cat\# M7514\                                                                     Used 100 nM final concentration
                                                                                                                                                         CAS: 201860-17-5                                                                 

  Chemical compound, drug                      Mitosox red superoxide indicator                                              ThermoFisher Scientific     Cat\# M36008                                                                     Used 5 μM final concentration

  Chemical compound, drug                      2-NBDG                                                                        ThermoFisher Scientific     Cat\# N13195                                                                     Used 10 μM final concentration

  Chemical compound, drug                      Fixable viability dye eFluor 455uv                                            ThermoFisher Scientific     Cat\# 65-868-14                                                                  Flow cytometry (0.5 μL per test)

  Chemical compound, drug                      Fixable viability dye eFluor 506                                              ThermoFisher Scientific     Cat\# 65-0866-14                                                                 Flow cytometry (0.5 μL per test)

  Chemical compound, drug                      Oligomycin                                                                    Abcam                       Cat\# ab141829; CAS: 1404-19-9                                                   Used 2 μM final concentration

  Chemical compound, drug                      Rotenone                                                                      Abcam                       Cat\# ab143145\                                                                  Used 1 μM final concentration
                                                                                                                                                         CAS: 83-79-4                                                                     

  Chemical compound, drug                      Antimycin A                                                                   Sigma-Aldrich               Cat\# A8674;\                                                                    Used 1 μM final concentration
                                                                                                                                                         CAS: 1397-94-0                                                                   

  Chemical compound, drug                      Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP)                   Santa Cruz Biotechnology    Cat\# sc203578\                                                                  Used 0.5 μM final concentration
                                                                                                                                                         CAS: 370-86-5                                                                    

  Chemical compound, drug                      Phorbol 12-myristate 13-acetate (PMA)                                         Sigma-Aldrich               Cat\# P8139;\                                                                    Used 20 ng/mL final concentration
                                                                                                                                                         CAS: 16561-29-8                                                                  

  Chemical compound, drug                      Ionomycin calcium salt from *Streptomyces conglobatus*                        Sigma-Aldrich               Cat\# I0634;\                                                                    Used 1 μg/mL final concentration
                                                                                                                                                         CAS: 56092-82-1                                                                  

  Chemical compound, drug                      Brefeldin A                                                                   Cell Signaling Technology   Cat\# 9972S;\                                                                    Used 10 μg/mL final concentration
                                                                                                                                                         CAS: 20350-15-6                                                                  

  Chemical compound, drug                      BCA protein assay kit                                                         ThermoFisher Scientific     Cat\# 23227                                                                      

  Chemical compound, drug                      Seahorse XF24 FluxPak                                                         Agilent                     Cat\# 102070--00                                                                 

  Chemical compound, drug                      Foxp3/Transcription factor staining buffer set                                ThermoFisher Scientific     Cat\# 00-5523-00                                                                 

  Chemical compound, drug                      TruSeq stranded mRNA library prep kit                                         Illumina                    Cat\# RS-122--2101                                                               

  Chemical compound, drug                      Dynabeads sheep anti-rat IgG                                                  ThermoFisher Scientific     Cat \# 11035                                                                     

  Software, algorithm                          STRING                                                                        [@bib53]                    <https://string-db.org/>                                                         

  Software, algorithm                          DAVID                                                                         [@bib20]                    <https://david-d.ncifcrf.gov/>                                                   

  Other                                        Thioglycollate medium                                                         Sigma-Aldrich               Cat\# T9032                                                                      

  Other                                        Bovine serum albumin, fatty acid free                                         Gemini Bio-Products         Cat\# 700--107P                                                                  

  Other                                        Collagen I protein, rat tail                                                  ThermoFisher Scientific     Cat\# A1048301                                                                   

  Other                                        Collagenase type IV                                                           ThermoFisher Scientific     Cat\# 17104019                                                                   

  Other                                        Recombinant DNase I, RNase-free                                               Affymetrix                  Cat\# 78411                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reagents {#s4-1}
--------

Lipopolysaccharide (LPS) from *Escherichia coli* strain K-235 (L2143) was from Sigma-Aldrich. Recombinant murine Ifn-γ (315-05) and Il-4 (214--14) were from Peprotech. The ETC complex II inhibitor dimethyl malonate (136441) and the L-type amino acid transport inhibitor 2-amino-2-norbornanecarboxylic acid, or BCH, (A7902) were from Sigma-Aldrich.

Animals {#s4-2}
-------

All animal studies were approved by the Harvard Medical Area Standing Committee on Animal Research. Animals were housed in a pathogen-free barrier facility at the Harvard T.H. Chan School of Public Health. *Bmal1^fl/fl^* (stock \# 007668), *Hif1a ^fl/fl^* (stock \# 007561), and *Lyz2-Cre* (stock \# 004781) mice in the C57BL/6J background were obtained from Jackson laboratories and were originally contributed by Drs Charles Weitz, Dmitriy Lukashev, and Irmgard Foerster, respectively. Floxed mice were crossed with *Lyz2-Cre* mice to generate myeloid-specific *Bmal1* and *Hif1a* knockout mice. Myeloid-specific *Bmal1* knockout mice were crossed with *Hif1a^fl/fl^* mice, and the resulting heterozygotes were crossed to generate myeloid-specific *Bmal1* and *Hif1a* double-knockout mice. The genotypes were validated by both DNA genotyping and mRNA expression. Gender- and age-matched mice of between 8--24 weeks of age were used for experiments. Similar results were obtained from male and female mice.

Bone marrow-derived macrophage (BMDM) differentiation and cell culture {#s4-3}
----------------------------------------------------------------------

Macrophages were differentiated from primary mouse bone marrow from the femur and tibia using differentiation medium containing 30% L929-conditioned medium, 10% FBS, and pen-strep solution in low-glucose DMEM in 15-cm Petri dishes. Media were changed every three days, and cells were lifted, counted, and plated in final format in tissue culture plates on days 7--8 of differentiation. For experiments, primary macrophages were maintained in low glucose DMEM containing 10% FBS and pen-strep. For M1 activation, macrophages were primed with 10 ng/mL Ifn-γ for 10--12 hr and subsequently stimulated with 10 ng/mL of *E. coli* LPS at the start of each experiment. Macrophages with Ifn-γ priming but without LPS were used as the control for M1 activation.

Peritoneal and splenic macrophage isolation and culture {#s4-4}
-------------------------------------------------------

For peritoneal macrophage isolation, mice aged 2--4 months were *i.p.* injected with 3 mL of 3% thioglycollate (Sigma-Aldrich, T9032). After 3 days, mice were euthanized, and peritoneal cells were recovered by lavage. For isolation of splenic macrophages, mice were euthanized and spleens were dissected and mashed in growth medium (high glucose DMEM with 10% FBS) and passed through a 70 μm strainer. Cells were pelleted and resuspended in red blood cell lysis buffer. Monocytes and lymphocytes were recovered using Ficoll-Paque Plus density gradient medium (GE Healthcare Life Sciences, 17144002) according to the manufacturer's instructions, and suspension cells (lymphocytes) were washed away prior to experiments.

LPS synchronization of Bmal1 expression {#s4-5}
---------------------------------------

To synchronize *Bmal1* gene and protein expression with LPS (or LPS shock), BMDMs or mouse embryonic fibroblasts (MEFs) were given fresh culture medium with 2% FBS and 100 ng/mL LPS for 1 hr and then given fresh medium with 2% FBS without LPS. *Bmal1* expression was tracked following LPS removal. For M1 or LPS induction of *Bmal1* expression, cells were primed with or without 10 ng/mL Ifn-γ for 10--12 hr in DMEM, 10% FBS and subsequently stimulated with 10 ng/mL of LPS without changing the medium (time zero).

Cell lines {#s4-6}
----------

MEFs were isolated from WT C57/BL6J mouse embryos and immortalized using the 3T3 protocol as previously described ([@bib56]). For experiments, immortalized MEFs were maintained in growth medium containing high glucose DMEM, 10% FBS. RAW264.7 mouse macrophages (TIB-71) and B16-F10 mouse melanoma cells (CRL-6475) were purchased from ATCC and experiments were conducted using early passages. Mycoplasma contamination was monitored using PCR-based methods. For generation of stable Bmal1-overexpressing RAW264.7 cells, the *Bmal1* coding sequence was cloned from mouse embryonic cDNA (forward primer: 5′ GGCGAATTCGCGGACCAGAGAATGGAC 3′; reverse primer: 5′ GGGCTCGAGCTACAGCGGCCATGGCAA 3′) and subcloned into the pBABE retroviral expression vector (Addgene, 1764). Retroviral vectors were transfected into Phoenix packaging cells, followed by collection of supernatants containing retroviruses. RAW264.7 macrophages were incubated with retroviral supernatants with 4 µg/mL polybrene, and infected cells were selected with 4 µg/mL puromycin. Control cells were transduced with the empty pBABE vector.

Syngeneic tumor model and tumor measurement {#s4-7}
-------------------------------------------

Male and female WT and M-BKO mice aged 10--12 weeks were subcutaneously injected in the right flank with 300,000 B16-F10 mouse melanoma cells. For co-injection experiments, 500,000 B16-F10 cells were mixed with either 500,000 WT or M-BKO BMDMs (differentiation for 6 day) in the right and left flanks, respectively. Tumor dimensions were measured every two days by caliper after all mice had palpable tumors, and tumor volume was calculated as LxWxWx0.52 as previously described ([@bib8]). For DMM treatment, mice were switched to a soft pellet, high fat diet (Bio-Serv, F3282) so that DMM could be mixed with the diet using a blender. The tumor growth rate was slower on high fat diet ([Figure 7C](#fig7){ref-type="fig"}) compared to normal chow ([Figure 7A](#fig7){ref-type="fig"}).

RNA sequencing {#s4-8}
--------------

RNA-seq was performed on RNA from three biological replicates per treatment. Sequencing and raw data processing were conducted at the Institute of Molecular Biology (IMB) Genomics Core and IMB Bioinformatics Service Core, respectively, at Academia Sinica (Taipei, Taiwan, ROC). In brief, RNA was quantified using the Quant-iT ribogreen RNA reagent (ThermoFisher, R11491), and RNA quality was determined using a Bioanalyzer 2100 (Agilent; RIN \> 8, OD 260/280 and OD 260/230 \> 1.8). RNA libraries were prepared using the TruSeq Stranded mRNA Library Preparation Kit (Illumina, RS-122--2101). Sequencing was analyzed with an Illumina NextSeq 500 instrument. Raw data were analyzed using the CLC Genomics Workbench. Raw sequencing reads were trimmed by removing adapter sequences, low-quality sequences (Phred quality score of \<20) and sequences \>25 bp in length. The trimmed reads were then mapped to the mouse genome assembly (mm10) from University of California, Santa Cruz, using the following parameters: mismatches = 2, minimum fraction length = 0.9, minimum fraction similarity = 0.9, and maximum hits per read = 5. Gene expression was determined by the number of transcripts per kilobase million. Functional annotation clustering of differentially regulated genes was done using DAVID (<https://david-d.ncifcrf.gov/>), and the interaction maps of transcriptional regulators that were induced or repressed by M1 activation that are shown in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} were generated using STRING (<https://string-db.org/>). Significantly changed genes were determined by p\<0.05 and FDR \<0.05. Data have been deposited in GEO under the accession number GSE148510.

qPCR {#s4-9}
----

Relative gene expression was determined by real-time qPCR with SYBR Green. The expression of the ribosomal subunit *36b4* (*Rplp0*) was used as an internal control to normalize expression data. Primer information is described in the \'Key resources table\'.

Western blot {#s4-10}
------------

Standard Tris-Glycine SDS-PAGEs were run and transferred to PVDF membranes by wet transfer. Membranes were incubated with primary antibodies in TBST buffer with 1% BSA overnight. ECL signal was imaged using a BioRad ChemiDoc XRS+ imaging system. The antibody for Bmal1 (sc365645) was from Santa Cruz. The antibody for Hif-1α (NB100-449) was from Novus Biologicals. The antibodies for β-tubulin (2146) and β-actin (4970) were from Cell Signaling Technology.

Extracellular flux analyses {#s4-11}
---------------------------

Extracellular flux experiments were done using a Seahorse XF24 analyzer (Agilent) and FluxPaks (Agilent, 100850--001). 200,000 BMDMs, splenic/peritoneal macrophages or RAW264.7 cells were seeded into Seahorse XF24 plates for extracellular flux experiments. Minimal DMEM (pH 7.4) without phenol red and containing energy substrates as indicated was used as the assay medium. 2% dialyzed FBS was added to media for experiments in which LPS was injected during the assay to enhance responsiveness to LPS. Assay measurements were normalized to total protein content.

Glucose uptake assay {#s4-12}
--------------------

BMDMs were plated at a density of 1 million cells per well in 12-well plates and stimulated as indicated. Cells were then washed with Krebs-Ringer bicarbonate HEPES (KRBH) buffer and then given 400 μL with KRBH buffer loaded with 0.8 μCi/well \[^3^H\]−2-deoxyglucose (PerkinElmer, NET549A001MC) and 0.5 mM unlabeled 2-deoxyglucose and incubated at 37°C for 30 min. 10 μL of 1.5 mM Cytochalasin B (Cayman Chemical, 11328) was then added to stop glucose uptake. 400 μL of lysate was used to measure levels of \[^3^H\]−2-deoxyglucose by a scintillation counter, and the remaining lysate was used to measure total protein content for normalization.

Measurement of lactic acid secretion {#s4-13}
------------------------------------

Lactic acid was measured in the supernatants of BMDMs using the Biovision Lactate Colorimetric Kit (K627) according to the manufacturer's protocol. Readings were normalized to total cellular protein content.

Mitochondrial isolation {#s4-14}
-----------------------

Mitochondria were isolated from primary BMDMs by differential centrifugation. In brief, cells were resuspended in 500 μL of ice-cold mitochondrial isolation buffer consisting of 70 mM sucrose, 50 mM Tris, 50 mM KCl, 10 mM EDTA, and 0.2% fatty-acid free BSA (pH 7.2) and then extruded through 29-gauge syringes 20 times. Lysates were spun at 800 g to pellet nuclei, and supernatants were spun at 8000 g to isolate mitochondria. Pelleted mitochondria were washed once more with 500 μL of mitochondria isolation buffer. Total mitochondrial protein content was determined by BCA assay.

ETC activity assays in isolated mitochondria {#s4-15}
--------------------------------------------

The activities of ETC complexes I--IV were measured in isolated mitochondria using colorimetric assays as previously described ([@bib47]) with modifications. In brief, 15 μg of mitochondria were loaded per reaction for complexes III and IV, and 30 and 50 μg were used for complexes II and I, respectively. Complex I activity was determined by the decrease in absorbance at 340 nm corresponding to reduction of ubiquinone by electrons from NADH. Complex II activity was determined by the decrease in absorbance at 600 nm corresponding to reduction of decylubiquinone by electrons from succinate. Complex III activity was determined by the increase in absorbance at 550 nm corresponding to reduction of cytochrome C. Complex IV activity was determined by decrease in absorbance at 550 nm corresponding to oxidation of cytochrome C.

Flow cytometry {#s4-16}
--------------

For flow cytometry, BMDMs were seeded into low-attachment plates for the indicated treatments and resuspended by pipetting. Mitochondrial content in BMDMs was determined by flow cytometry of live cells stained with 100 μM Mitotracker Green FM (ThermoFisher, M7514) according to the manufacturer's instructions.

For flow cytometry of tumor-infiltrating lymphocytes, cells were stimulated ex vivo with 20 ng/mL phorbol 12-myristate 13-acetate (PM), (Sigma-Aldrich, P8139) and 1 μg/mL ionomycin (Sigma-Aldrich, I0634) for 4 hr and co-treated with brefeldin A (Cell Signaling Technology, 9972) to inhibit cytokine release. Cells were stained with the fixable viability dye (eFluor 455uv \[ThermoFisher, 65-868-14\] or eFluor 506 \[ThermoFisher, 65-0866-14\]) for 20 min at 4°C in PBS, washed, and incubated with antibodies against the indicated surface antigens for 30 min at 4°C in fluorescence-activated cell sorting (FACS) buffer (2% FBS and 1 mM EDTA in PBS). Cells were then washed twice and fixed with 2% paraformaldehyde for 1 hr at 4°C, and resuspended and stored in FACS buffer prior to downstream analysis. Immediately before flow cytometric analysis, cells were permeabilized for intracellular staining using the Foxp3/Transcription factor staining buffer set (ThermoFisher, 00-5523-00) according to the manufacturer's instructions. Of viable cells, CD8^+^ T cells were identified as CD45^+^CD3^+^CD8a^+^ cells and NK cells were identified by CD45^+^ CD3^--^ NK1.1^+^ staining. To determine glucose uptake and mROS production by primary TAMs, live cells were stained with either 5 μM Mitosox Red (ThermoFisher, M36008) or 10 μM 2-NBDG (ThermoFisher, N13195) for 20 min in RPMI 1640 medium at 37°C, then washed and resuspended in FACS buffer for flow cytometry. F480^+^ cells were gated from live CD45^+^ cells to measure the mean fluorescent intensities of Mitosox or 2-NBDG. Antibodies for PerCp/Cy5.5-conjugated CD45 (103132), PE/Cy7-conjugated CD3e (100320), Alexa Fluor 700-conjugated CD8a (100730), APC-conjugated NK1.1 (108710) Alexa 488-conjugated F480 (123120) and APC-conjugated F480 (123115) were from Biolegend. The antibody for PE-conjugated Ifn-γ (12-7311-81) was from ThermoFisher Scientific.

To measure ROS production by isolated mitochondria, 15 μg of mitochondria were resuspended in 500 μL mitochondrial isolation buffer containing 5 μM MitoSox Red and 100 μM MitoTracker Green FM with or without 10 mM sodium succinate. Mitochondria were incubated for 20 min at room temperature, washed with isolation buffer, and resuspended for flow cytometry. Mitochondria were identified by side scatter and positive MitoTracker Green staining for measurement of mean MitoSox Red intensity per population.

Steady-state metabolomics {#s4-17}
-------------------------

Untargeted metabolomics analysis using GC-TOF mass spectrometry was conducted by the West Coast Metabolomics Center at UC Davis. In brief, 10 million cells were lifted, pelleted, and washed twice with PBS for each replicate. Cell lysates were homogenized by metal bead beating, and metabolites were extracted using 80% methanol. Following extraction, cell pellets were solubilized using Tris-HCl urea buffer (pH 8.0) containing 1% SDS to measure cellular protein content for each sample. All metabolite readings were normalized to total protein content.

Collection of tumor-conditioned medium {#s4-18}
--------------------------------------

Mice bearing subcutaneous B16-F10 tumors were sacrificed 20 days after injection with 500,000 cells. Tumors were dissected and weighed. Tumors were minced in growth medium containing 10% dialyzed FBS in high-glucose DMEM (5 mL per gram of tissue) and incubated at 37°C for 2 hr. Conditioned medium was collected and filtered through a 100 μm strainer followed by three spins at 1,000 rpm to pellet and remove residual cells and debris from the medium.

Isolation of tumor-infiltrating immune cells {#s4-19}
--------------------------------------------

Subcutaneous mouse tumors were dissected, weighed, and then placed in six-well plates with growth medium (RPMI, 5% FBS) and minced. Minced tissues were combined into three groups per genotype, spun down in 50 mL conical tubes, and resuspended in 20 mL digestion buffer (0.5 mg/mL collagenase IV, 0.1 mg/mL DNase I in HBSS medium). Tumors were digested at 37°C with gentle shaking for 30 min and vortexed every 10 min. Contents were filtered through a 100 mm mesh, and cells were pelleted and resuspended in 45% percoll in 1X HBSS and 1X PBS. Cells were spun at 2000 rpm at 4°C with a swing bucket rotor for 20 min. The supernatant was aspirated, and the pellet was briefly resuspended in 5 mL ACK buffer to lyse red blood cells. Last, cells were pelleted and resuspended in growth medium for downstream applications.

To isolate F4/80^+^ cells from tumors, tissues were homogenized and processed as above to collect tumor-infiltrating leukocytes. F4/80^+^ cells were then isolated by positive selection using a rat anti-F4/80 antibody (Biolegend, 123120) and sheep anti-rat Dynabeads (ThermoFisher Scientific, 11035) according to the manufacturer's instructions.

Statistical analysis {#s4-20}
--------------------

All data are presented as mean ± SEM. GraphPad Prism 7 was used for statistical analyses. Two-tailed Student's t test was used for comparisons of two parameters. Two-way ANOVA was used for multi-parameter analyses for time course comparisons. Cell-based experiments were performed with 3--5 biological replicates (cell culture replicates). For tumor volume, outliers were determined using a Rout test (p\<0.05), and outliers were omitted from downstream experiments.
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Raw RNA-seq data on GEO: accession number GSE148510. All analyzed RNA-seq and metabolite data are included in the manuscript and source data for Figure 3 and Figure. 5.

The following dataset was generated:
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The study reveals the importance of the function of the circadian clock, through BMAL1, for the appropriate activation of the inflammatory response in macrophages. As such, it advances our understanding on the coordination between mitochondrial metabolism and inflammatory cascade towards the most appropriate macrophage response.

**Decision letter after peer review:**

Thank you for submitting your article \"Bmal1 integrates mitochondrial metabolism and macrophage activation\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Satyajit Rath as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript reports a cell-autonomous role for the circadian clock gene *Bmal* in the regulation of macrophage effector functions. Specifically, the authors find that macrophages deficient in Bmal1 upregulate the glycolytic capacity at the expense of mitochondrial function upon M1-like stimulation in a Hif-1α dependent manner. They also extend their findings in an in vivo tumor model, wherein Bmal deficiency results in improved anti-tumor response. Overall, the manuscript was found to be well written, the experiments properly controlled for and the results described supported by the authors\' conclusions.

Essential revisions:

1\) The manuscript mostly focuses on the role of Bmal in the regulation of M1-like stimulation. As such, it remains unclear whether the findings apply specifically to the role of Bmal in regulating metabolic reprogramming solely upon macrophage activation or also to the modulation of mitochondria metabolism in basal conditions.

2\) Related to the point raised above, there appears to be a disconnect between the kinetics of expression of different components upon M1 activation and the effects on mitochondria. For example, the initial identification of Bmal as a regulator of multiple transcriptional modules activated/repressed upon M1 activation is based on transcriptional profiling at a specific time point (8h after induction). Follow up studies reveal complex activation/repression kinetics and dependency on Bmal, however it is unclear how the different events relate to Bmal protein induction (which is shown to be peaking at 12h). In Figure 2 it is shown that mitochondrial content decreases as rapidly as 2h upon M1 induction when it is unknown whether Bmal induction/stabilization has already occurred. Moreover, the decrease is explained by an increase in mitophagy even though the increase in Bnip3 doesn\'t occur until 8h after activation. Downregulation of mitochondria biogenesis regulators PPARg and PPARd could contribute to the phenotype, but loss of Bmal seems to affect only their reactivation not the initial repression. Thus, it is unclear whether the authors interpret these results as Bmal induction in M1 activated macrophages being required for the long-term recovery of mitochondrial homeostasis or for the early decrease in mitochondrial function/content, in which case the mechanism is unclear.

3\) The findings on tumor associated macrophages (TAMs) need to be extended. Specifically, do TAMs derived from tumors display a similar regulation of Bmal1-mitochondrial capacity and glucose utilization as bone marrow-derived macrophages exposed to tumor derived conditioned medium?

4\) The data presented in Figure 1---figure supplement 1 indicate that the clock program downstream of Bmal is activated upon M1 induction. This raises a number of questions about the relationship between Bmal role in metabolic regulation and its well-known activity as a molecular clock. Discussing these findings in light of existing literature would be helpful for the audience to understand their possible implications in terms of circadian regulation of immunometabolism.
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Author response

> Essential revisions:
>
> 1\) The manuscript mostly focuses on the role of Bmal in the regulation of M1-like stimulation. As such, it remains unclear whether the findings apply specifically to the role of Bmal in regulating metabolic reprogramming solely upon macrophage activation or also to the modulation of mitochondria metabolism in basal conditions.

As the reviewers might be aware of, macrophages exhibit a spectrum of activation states. For our basal condition, cells were withdrawn from the differentiation medium (with L929 conditioned medium) and changed to DMEM, 10% FBS for the subsequence experiments. In the original (and the revised) Figure 2E, we showed the ECAR was the same between WT and M-BKO macrophages at the basal/unstimulated state.

To specifically address this question, we have performed Mitostress tests and measured mitochondrial respiration (oxygen consumption rate, OCR) under the basal condition or with a two-hour serum shock (50% FBS) that is known to synchronize circadian clock/Bmal1 expression in cultured cells. As shown in revised Figure 2---figure supplement 1C, there was no significant difference in the OCR between WT and M-BKO macrophages, with or without serum shock. We could not rule out the possibility that in vivo, Bmal1 deficiency may affect macrophage mitochondrial metabolism in an unstimulated state when energy substrate availability changes between feeding and fasting states. It would appear that under the experimental condition, Bmal1- mediated mitochondrial metabolism is more important in M1-activated macrophages.

> 2\) Related to the point raised above, there appears to be a disconnect between the kinetics of expression of different components upon M1 activation and the effects on mitochondria. For example, the initial identification of Bmal as a regulator of multiple transcriptional modules activated/repressed upon M1 activation is based on transcriptional profiling at a specific time point (8h after induction). Follow up studies reveal complex activation/repression kinetics and dependency on Bmal, however it is unclear how the different events relate to Bmal protein induction (which is shown to be peaking at 12h). In Figure 2 it is shown that mitochondrial content decreases as rapidly as 2h upon M1 induction when it is unknown whether Bmal induction/stabilization has already occurred. Moreover, the decrease is explained by an increase in mitophagy even though the increase in Bnip3 doesn\'t occur until 8h after activation.

We agree there is a discordance between the peak protein accumulation and functional outcomes, which might be partly due to the limitation in detection sensitivity of immunoblotting. For instance, Hif-1α protein accumulation was detectable at 4 hour and peaked at 8 hours following M1 activation (Figure 4A). However, Hif-1α dependent glucose uptake and lactate production were evident at 4 hours (Figure 3C and 3D and Figure 4---figure supplement 1B and 1C). Bmal1 protein has already accumulated at 4 hours (Figure 1A) and a higher Hif-1α protein level was observed in M-BKO macrophages at this time point (Figure 4A). We have included in [Author response image 1](#respfig1){ref-type="fig"} the lactate production result with the 2-hour time point for the review purpose. Lactate release was induced by M1 activation at 2 hours in WT macrophages, which was further up regulated in M-BKO macrophages. As such Bmal1 is likely to have functional importance at early time points after M1 activation.
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We have conducted new Mitostress test to examine mitochondrial respiration in unstimulated, 2-hour M1 or 6-hour M1 activation. As shown in the revised Figure 2---figure supplement 1B, 2h M1 activation suppressed mainly the basal OCR, while 6h M1 affected both basal and maximum respiration in WT macrophages. The suppressed mitochondrial respiration was to a greater extent in M-BKO macrophages at both time points. The comparison and statistical analysis of the basal OCR is presented in the revised Figure 2B. While the 6hr effect could be partly explained by Bnip3-mediated mitophagy, the 2hr effect could not, as pointed out by the reviewers. In fact, Figure 2C showed that given the same amount of protein, mitochondria isolated by M1 activated M-BKO had lower ETC complex activities, suggesting that M-BKO impacted mitochondrial quality as well. We have moved the Bnip3 immunoblotting to Figure 2---figure supplement 1A and modified the description by stating that the reduced mitochondrial content was accompanied by elevated Bnip3 protein levels. Potential underlying mechanisms for the early phase effect is described below.

> Downregulation of mitochondria biogenesis regulators PPARg and PPARd could contribute to the phenotype, but loss of Bmal seems to affect only their reactivation not the initial repression. Thus, it is unclear whether the authors interpret these results as Bmal induction in M1 activated macrophages being required for the long-term recovery of mitochondrial homeostasis or for the early decrease in mitochondrial function/content, in which case the mechanism is unclear.

As discussed in point 2.1, results in the revised Figure 2---figure supplement 1B (and Figure 2B) confirmed that M-BKO indeed affected mitochondrial respiration in the early phase of M1 activation. To assess the recovery phase, we conducted parallel Mitostress tests with either serum shock or "LPS shock" synchronization. The inclusion of serum shock served two purposes: the first was to examine whether Bmal1 gene deletion affected basal respiration, as discussed in point 1, and the second was to provide as a reference for potential effects from medium change at the recovery phase. For these experiments, macrophages were given a 2-h serum shock (DMEM, 50% FBS) or acute LPS treatment (DMEM, 2% FBS, which induced Bmal1 gene/protein expression shown in Figure 1C), washed and cultured in DEME, 10% FBS or DMEM, 2% FBS, respectively, for additional 24 hours before the Mitostress tests. The use of 2% FBS in the acute LPS treatment was to further reduce any potential serum effects on synchronization. As mentioned in point 1, there was no genotypic difference in OCR under serum shock synchronization (revised Figure 2---figure supplement 1C). By contrast, the basal OCR of M-BKO macrophages remained suppressed 24 hours following the acute LPS treatment, while the basal OCR was completely recovered in WT macrophages (revised Figure 2---figure supplement 1D). Collectively, these results suggest that Bmal1 gene deletion impacts macrophage mitochondrial respiration both during and at the recovery phase of M1 stimulation.

For the early stage effect, we think one of the plausible mechanisms is through modulation of Hif-1α activation, as discussed in point 2.1. Hif-1α-mediated glycolysis drives pyruvate away from TCA cycle and towards lactate production. Increased lactate production was observed in M-BKO macrophages at 2hr following M1 activation (see [Author response image 1](#respfig1){ref-type="fig"}). It could also be mediated by downstream pathways of the circadian regulatory network. Notably, the Nr1d1/Nr1d2 nuclear receptor family members have been shown to negatively regulate macrophage inflammatory gene expression (Lam et al., 2013). The induction of Nr1d2 by M1 was almost completely abolished in M-BKO macrophages (Figure 1D). In concert, the expression of *Cx3cr1*, a direct target suppressed by Nr1d1/Nr1d2 (Lamet al., 2013), was higher in M1 activated M-BKO macrophages, compared to WT cells (Figure 5---source data 1). This suppressive effect of Nr1d1/Nr1d2 may dampen the inflammatory damage to mitochondrial function at the initial stage of M1 activation. We have discussed these potential mechanisms in the revised Discussion section.

> 3\) The findings on tumor associated macrophages (TAMs) need to be extended. Specifically, do TAMs derived from tumors display a similar regulation of Bmal1-mitochondrial capacity and glucose utilization as bone marrow-derived macrophages exposed to tumor derived conditioned medium?

We agree it's important that the proposed mechanism could be demonstrated in TAMs derived from tumors. Unfortunately, it is technically challenging to obtain sufficient TAMs from mouse tumor models for functional assays, such as mitochondrial respiration and glucose utilization. Using flow cytometry, we were able to stain F4/80+ cells from tumor lysate with 2NBDG, a fluorescent glucose analog, and Mitosox red to assess glucose uptake and mROS levels, respectively. As showed in the revised Figure 6---figure supplement 1A-1C, M-BKO TAMs from primary tumors also exhibited increased glucose uptake and mROS production, compared to WT TAMs.

> 4\) The data presented in Figure 1---figure supplement 1 indicate that the clock program downstream of Bmal is activated upon M1 induction. This raises a number of questions about the relationship between Bmal role in metabolic regulation and its well-known activity as a molecular clock. Discussing these findings in light of existing literature would be helpful for the audience to understand their possible implications in terms of circadian regulation of immunometabolism.

We agree with the reviewers that Bmal1 is best known for its role as a master circadian regulator and our RNA-seq data indicate the clock program downstream of Bmal1 is activated by M1 activation. Studies have shown that certain components of the molecular clock are capably of suppressing the expression of inflammatory genes, including Nr1d1/Nr1d2 nuclear receptor family members discussed in point 2.2. Bmal1 has also been shown to regulate diurnal monocyte trafficking that appears to play an important role in immune response against pathogens and in limiting inflammatory damage (Nguyen et al., 2013). We think that as a circadian regulator, Bmal1 could modulate inflammatory gene expression through downstream effectors, such as Nr1d1/Nr1d2. As a metabolic regulator, Bmal1-mediated energetic control may provide energy needed for diurnal monocyte trafficking/migration. In the context of infection or LPS/M1 activation, Bmal1 may regulate the timing of glycolytic to oxidative metabolism transition that dictates the extent of Hif-1α activation and the associated inflammatory response/damage. As suggested by the reviewers, we have incorporated these points into the second paragraph of the Discussion.
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